Truqap (capivasertib)
capivasertib 200 mg tablet, 64 · ORAL · PBS code 15059N
AUTHORITY_REQUIREDWhat it costs
AU$8397 PBS-determined price per 64 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2025-10-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Locally advanced or metastatic breast cancer
The condition must be human epidermal growth factor receptor 2 (HER2) negative; AND
The condition must be estrogen receptor positive; AND
The treatment must be in combination with fulvestrant; AND
The treatment must be following progression on at least one endocrine-based regimen in the metastatic setting; or
The treatment must be following recurrence on or within 12 months of completing endocrine-based adjuvant therapy.
A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.
Confirm that the following information is documented/retained in the patient's medical records once only with the first PBS prescription:
1) Evidence of HER2 negative status (evidence obtained in relation to past PBS treatment is acceptable).
2) Evidence of HR status.
Sponsor: AstraZeneca Pty Ltd ABN 54 009 682 311
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.